共 6 条
[1]
Early virologic response after peginterferon alpha‐2a plus ribavirin or peginterferon alpha‐2b plus ribavirin treatment in patients with chronic hepatitis C*[J] . A. M.Di Bisceglie,R. H.Ghalib,F. M.Hamzeh,V. K.Rustgi.Journal of Viral Hepatitis . 2007 (10)
[2]
Changing of hepatitis C virus genotype patterns in France at the beginning of the third millenium: The GEMHEP GenoCII Study[J] . C.Payan,F.Roudot‐Thoraval,P.Marcellin,N.Bled,G.Duverlie,I.Fouchard‐Hubert,P.Trimoulet,P.Couzigou,D.Cointe,C.Chaput,C.Henquell,A.Abergel,J. M.Pawlotsky,C.Hezode,M.Coudé,A.Blanchi,S.Alain,V.Loustaud‐Ratti,P.Chevallier,C.Trepo,V.Gerolami,I.Portal,P.Halfon,M.Bourlière,M.Bogard,E.Plouvier,C.Laffont,G.Agius,C.Silvain,V.Brodard,G.Thiefin,C.Buffet‐Janvresse,G.Riachi,F.Grattard
[4]
Meta‐analysis: a randomized trial of peginterferon plus ribavirin for the initial treatment of chronic hepatitis C genotype 4[J] . Mohammad S.Khuroo,Mehnaaz S.Khuroo,Salim T.Dahab.Alimentary Pharmacology & Therapeutics . 2004 (9)
[5]
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial[J] . Michael P Manns,John G McHutchison,Stuart C Gordon,Vinod K Rustgi,Mitchell Shiffman,Robert Reindollar,Zachary D Goodman,Kenneth Koury,Mei-Hsiu Ling,Janice K Albrecht.The Lancet . 2001 (9286)